Clinical Trials Directory

A Phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard (NM) 0.02% Ointment Formulations in Patients With Stage I or IIA Mycosis Fungoides (MF)

This study will evaluate the efficacy, tolerability and safety of the topical application of mechlorethamine (MCH) formulations in patients with stage I or IIA mycosis fungoides (MF).

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : mechlorethamine-MCH (nitrogen mustard)

Phase: Phase 2


Ages Eligible For Study:

N/A - N/A

Inclusion Criteria

- Patients with mycosis fungoides confirmed by a skin biopsy - Stage I or IIA patients must have been treated previously with prior topical therapies including PUVA, UVB, topical steroids, but not NM within the past 2 years, or topical carmustine (BCNU) - Patients must be otherwise healthy with acceptable organ function. - Prior to initiating study therapy, patients must not have had topical therapy within four weeks - Lab values within normal range - Willing/able to give consent - Must use effective means of contraception if of childbearing potential

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Natalie Viakhireva
Not Recruiting

Footer Links: